Geron Corporation (NASDAQ: GERN) is up 15% in pre-market after announcing the publication of a paper in the Annals of Hematology titled, “Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data.”
The paper details statistical analysis of data comparing findings from the IMbark second phase clinical study to Real-World Data. Chief Medical Officer Aleksandra Rizo said that the overall survival in various analyses published in the paper for imetelstat-treated patients in the IMbark second phase clinical study was more than double the overall median survival in patients treated with standard therapy.
The publication highlights multiple statistical adjustment methods and various sensitivity analyses seeking to enhance data set compatibility from Geron’sIMbark second phase study and RWD to imitate the impact of a randomized trial. The authors pointed out consistencies in statistical significance and hazard ratios observed in the different analyses, suggesting survival benefits related to imetelstat treatment after ruxolitinib failure. So, GERN is worth keeping an eye on in the coming days.
Market Reaction:
On Monday, GERN stock jumped 1.527% at $1.3400 with more than 789k shares, compared to its average volume of 1 million shares. The stock has moved within a range of $1.3100 – 1.3500 after opening the trade at $1.3100.
